Sang Tan/Associated Press
GlaxoSmithKline hung on to its perennial top spot in the new Access to Medicines Index released last week, but its competitors are closing in.
Every two years, the index ranks the world’s top 20 pharmaceutical companies based on how readily they get medicines they hold patents on to the world’s poor, how much research they do on tropical diseases, how ethically they conduct clinical trials in poor countries, and similar issues.
Johnson & Johnson shot up to second place, while AstraZeneca fell to 16th from 7th. AstraZeneca has had major management shake-ups. It did not do less, but the industry is improving so rapidly that others outscored it, the report said.
The index was greeted with skepticism by some drugmakers when it was introduced in 2008. But now 19 of the 20 companies have a board member or subcommittee tracking how well they do at what the index measures, said David Sampson, the chief author.
The one exception was a Japanese company. As before, Japanese drugmakers ranked at or near the index’s bottom, and European companies clustered near the top. Generic companies — most of them Indian — that export to poor countries are ranked separately.
Johnson & Johnson moved up because it created an access team, disclosed more and bought Crucell, a vaccine company.
The foundation that creates the index now has enough money to continue for five more years, said its founder, Wim Leereveld, a former pharmaceutical executive.
Global Update: GlaxoSmithKline Tops Access to Medicines Index
This article
Global Update: GlaxoSmithKline Tops Access to Medicines Index
can be opened in url
https://kikonewster.blogspot.com/2012/12/global-update-glaxosmithkline-tops.html
Global Update: GlaxoSmithKline Tops Access to Medicines Index
